Xanthine Analogs Suppress Trypanosoma cruzi Infection In Vitro Using PDEs as Targets

Trypanosoma cruzi (T. cruzi), the causative agent of Chagas disease, has infected 6 million people, putting 70 people at risk worldwide. Presently, very limited drugs are available, and these have severe side effects. Hence, there is an urgency to delve into other pathways targets for novel drugs. cruzi) expresses a number different cyclic AMP (cAMP)-specific phosphodiesterases (PDEs). cAMP one key regulators mammalian cell proliferation differentiation, it also plays important role in T. growth. Very few studies demonstrated nucleotide-specific PDEs cruzi’s survival. phosphodiesterase C (TcrPDEC) been proposed as potential new drug target treating disease. In current study, we screen several analogs xanthine potency against trypomastigote amastigote growth vitro using three strains (Tulahuen, Y CA-1/CL72). One potent analogs, GVK14, shown inhibit all amastigotes host cells well axenic cultures. conclusion, that PDE may provide alternative therapeutic options